Evidence map›Paper›PMID 39356394›Full record

ArticleBreast cancer research and treatment2025

Development of a novel prediction model for carriage of BRCA1/2 pathogenic variant in Japanese patients with breast cancer based on Japanese organization of hereditary breast and ovarian cancer registry data.

Nana Komatsu, Takashi Chishima, Chie Watanabe, Kanae Taruno, Mayuko Inuzuka, Masanori Oshi, Masami Arai, Seigo Nakamura

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Nana KomatsuDepartment of Breast Surgery, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-Chuo, Tsuduki, Yokohama, Kanagawa, 224-8503, Japan.
Takashi ChishimaDepartment of Breast Surgery, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-Chuo, Tsuduki, Yokohama, Kanagawa, 224-8503, Japan. chishima-t@med.showa-u.ac.jp.
Chie WatanabeDivision of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Shinagawa, Tokyo, Japan.
Kanae TarunoDivision of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Shinagawa, Tokyo, Japan.
Mayuko InuzukaDivision of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Shinagawa, Tokyo, Japan.
Masanori OshiDepartment of Breast Surgery, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-Chuo, Tsuduki, Yokohama, Kanagawa, 224-8503, Japan.
Masami AraiDepartment of Clinical Genetics, Graduate School of Medicine, Juntendo University, Bunkyo, Tokyo, Japan.
Seigo NakamuraDivision of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Shinagawa, Tokyo, Japan. seigonak@med.showa-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWith the increasing demand for BRCA genetic testing, most existing prediction models were developed using data from individuals of European descent. This study aimed to identify clinicopathological factors of hereditary breast and ovarian cancer (HBOC) syndrome and develop the first Japanese-specific prediction model for BRCA pathogenic variant carriers in Japan.

methodsWe utilized data from 3072 Japanese patients with breast cancer aggregated by the Japanese Organization of Hereditary Breast and Ovarian Cancer registry. Prediction models were developed using 70% of the overall dataset and validated using the remaining 30%. Factors associated with the BRCA pathogenic variant status were identified using logistic univariate analysis, and significant factors were further analyzed using logistic multivariate analysis to develop prediction models for BRCA1/2 (BRCA1 and/or BRCA2), BRCA1, and BRCA2 pathogenic variants.

resultsBRCA1 showed associations with aggressive clinicopathological factors such as triple-negative breast cancer and nuclear grade 3. Moreover, the prediction model showed a high area under the curve (AUC) of 0.879. By contrast, BRCA2 exhibited fewer characteristic associated factors, and the AUC of the model was 0.669. Common factors shared by BRCA1/2, BRCA1, and BRCA2 were the age at diagnosis of breast cancer and the youngest age of relatives with breast cancer. Consistent with previous research, early-onset breast cancer appeared to be strongly associated with HBOC.

conclusionWe successfully developed prediction models for BRCA1/2, BRCA1, and BRCA2 pathogenic variants. By accurately stratifying patients' risk and guiding targeted screening and preventative interventions, these models will contribute to improved management and outcomes of HBOC.

Indexed as

BRCA1 ProteinBRCA2 ProteinBreast NeoplasmsHereditary Breast and Ovarian Cancer SyndromeAdultAgedEast Asian PeopleFemaleGenetic Predisposition to DiseaseGenetic TestingHeterozygoteHumansJapanMiddle AgedMutationRegistriesBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanBRCA genetic testingBreast cancerHereditary breast and ovarian cancer syndromePrediction model

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.